Economic Analysis of Neoadjuvant Chemotherapy Versus Primary Debulking Surgery for Advanced Epithelial Ovarian Cancer Using an Aggressive Surgical Paradigm
Conclusions
In the short term, NACT is cost-saving with improved outcomes. However, if PDS provides a longer-term survival advantage, it may be cost-effective. Research is needed on the role of patient preferences in tradeoffs between survival and quality of life.
Source: International Journal of Gynecological Cancer - Category: Cancer & Oncology Tags: Ovarian Cancer Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Epithelial Cancer | Medicare | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Ovarian Cancer | Ovaries | USA Health